Sarcoma,Soft Tissue Clinical Trial
— PASART-1Official title:
Phase I Clinical Study of a Combined Modality Treatment of Sarcomas of the Extremities With Radiotherapy (RT) and Dose-escalation of Pazopanib
In this study, we aim to define the recommended dose of a VEGFR-TKI (pazopanib) in combination with RT pre-operatively given.
Status | Completed |
Enrollment | 12 |
Est. completion date | November 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma of and localized to the extremities or head and neck area for which the treatment is a combination of both surgery and radiotherapy (deep seated, > 5cm according to the RECIST 1.1 criteria, grade II/III according to the WHO definition). 2. Age > 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 5. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations. 6 Able to swallow and retain oral medication. 7. A life expectancy of at least 12 weeks. 8. Adequate organ function. Exclusion Criteria: 1. Prior malignancies; except subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. 2. Patients with recurrent sarcomas (even without prior radiotherapy). 3. Ewing sarcoma and other PNET family tumours, rhabdomyosarcomas (both pediatric and adult), osteosarcomas. 4. Clinically significant gastrointestinal abnormalities which might interfere with oral dosing diagnosed as: - Active peptic ulcer disease. - Known intraluminal metastatic lesions with suspected bleeding. - Inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation. - History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment. - Major resection of the stomach or small bowel. 5. Uncontrolled hypertension. 6. Unstable or serious concurrent condition (e.g., active infection requiring systemic therapy). 7. Prolongation of corrected QT interval (QTc) >480 msecs. 8. History of any one of more of the following cardiovascular conditions within the past 6 months: 1. Cardiac angioplasty or stenting. 2. Myocardial infarction. 3. Unstable angina. 4. Symptomatic peripheral vascular disease. 5. Coronary artery by-pass graft surgery. 6. Class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA). 7. History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. 9. Macroscopic hematuria 10. Haemoptysis that is clinically relevant within 4 weeks of first dose of study drug. 11. Evidence of active bleeding or bleeding diathesis. 12. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer. 13. Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study drug. 14. Biological therapy or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug. 15. Prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to Visit 1 and for the duration of the study should not be taken. 16. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib. 17. Pregnancy or lactating. 18. Hypothyroidism. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | The Netherlands Cancer Institute | Amsterdam | Noord Holland |
Lead Sponsor | Collaborator |
---|---|
The Netherlands Cancer Institute | GlaxoSmithKline |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity | To study the safety and feasibility of adding 6 weeks of orally administered Pazopanib to 25 x 2Gy in 5 weeks preoperative radiotherapy in extremity or head and neck area soft tissue sarcoma patients (to identify the Dose Limiting Toxicity (DLT) and the Recommend Phase II Dose (RPTD) if pazopanib is added to 50 Gy pre-operatively) | 14 weeks | Yes |
Secondary | the exploration/feasibility of dynamic imaging | The secondary objective is to explore the feasibility to perform perfusion weighted MRI imaging regarding tumor respons to RT and neoangio genesis inhibitor by pazopanib. | 14 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06114004 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
|
Phase 2 | |
Completed |
NCT01949506 -
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
|
N/A | |
Recruiting |
NCT04595994 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
|
Phase 1 | |
Recruiting |
NCT05235100 -
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Completed |
NCT04991883 -
Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
|
||
Recruiting |
NCT04122872 -
GISAR German Interdisciplinary Sarcoma Registry
|
||
Recruiting |
NCT04910126 -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT04219202 -
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
Recruiting |
NCT05167994 -
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Recruiting |
NCT04673942 -
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05813327 -
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04172805 -
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT04887298 -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03600649 -
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
|
Phase 1 | |
Recruiting |
NCT05894018 -
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT06263231 -
A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
|
Phase 3 | |
Recruiting |
NCT05614375 -
Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus
|